Tuesday, May 14, 2024 4:31:59 PM
We have finalized clinical trial agreement terms with five large academic institutions and are awaiting these sites to complete their final internal start-up activities before patients are enrolled," stated Vince Angotti, CEO of Talphera. "While the initial site activation has taken longer than expected, based on our ongoing discussions with the principal investigators, they are eager to get started and expect the trial will complete quickly given the primary endpoint is measured at 24 hours. As a result of the initial delays, we expect that our previous guidance of having top-line data available by September 30 will be revised. Once patients begin enrolling, we plan to provide an updated expected study completion date.
Kiwi
Recent TLPH News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 09:01:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:31:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:10:24 PM
- Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/13/2026 08:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/12/2026 05:22:56 PM
- Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026 • PR Newswire (US) • 05/07/2026 08:05:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2026 08:34:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 08:31:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 10:10:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 10:09:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/02/2026 04:15:30 AM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 04/01/2026 08:37:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 11:57:56 PM
- Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 • PR Newswire (US) • 03/25/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/23/2026 08:05:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:35:09 PM
- Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/23/2026 12:30:00 PM
- Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026 • PR Newswire (US) • 03/18/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 12:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:05:21 PM
- Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial • PR Newswire (US) • 03/02/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2026 01:28:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2026 01:27:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2026 01:23:20 AM
